Abstract:Therapeutic Advances in Drug Safety, Volume 15, Issue , January-December 2024. Background:Linezolid-induced anemia (LI-AN) is a severe adverse reaction, but risk factors of the LI-AN for elderly patients have not been established.Objectives:The objective of this study was to develop a nomogram capable of predicting LI-AN in elderly patients.Design:This is a retrospective study to develop and validate a nomogram for anemia prediction in elderly patients treated with linezolid.Methods:We retrospectively screened elderly patients treated with linezolid at Inner Mongolia People's Hospital from January 2020 to December 2023 and validated our findings using the MIMIC-IV 2.2 database. Anemia was defined as hemoglobin reduction to 75% of baseline value. Univariate and multivariable logistic regression models were used to identify predictors and construct the nomogram, which was evaluated using receiver operating characteristic (ROC) curve analysis, calibration plot, and decision curve analysis.Results:A total of 231 patients were enrolled in this study. The training set comprised 151 individuals, and anemia occurred in 28 cases (18.54%). In the external validation set of 80 individuals, 26 (32.5%) were diagnosed with anemia. The predictors included duration of linezolid therapy, patient estimated glomerular filtration rate value, and sequential organ failure assessment score ⩾2. The ROC curve for the training set was 0.830 (95% CI: 0.750–0.910), while a similar ROC curve of 0.743 (95% CI: 0.621–0.865) was obtained for the validation set. The calibration curve demonstrated good correlation between predicted and observed results, indicating that this study effectively predicts risk factors associated with LI-AN in elderly patients.Conclusion:The developed prediction model can provide valuable guidance for clinicians to prevent anemia and facilitate rational linezolid use in elderly patients.Plain language summaryStudy analyzing the clinical data of elderly patients using linezolid to better understand what factors may contribute to anemia in patientsWhy was the study done? This study aimed to develop a tool that predicts the risk of anemia in elderly patients treated with linezolid, a medication that can cause severe side effects like low hemoglobin levels. Identifying factors that contribute to this adverse reaction can help doctors prevent it and ensure safer use of linezolid.What did the researchers do? The researchers studied the medical records of elderly patients treated with linezolid at Inner Mongolia People's Hospital over a 4-year period. To better understand which factors are related to the occurrence of anemia, so we can find ways to predict the occurrence of problems.What did the researchers find? Factors that increase the risk of anemia after using linezolid include the duration of use of linezolid, kidney function, and SOFA score, that is, the longer the use of linezolid, the worse the kidney function, the higher the SOFA score, and the more likely the patient is to develop anemia.What do the findings mean? The researchers successfully created a tool, called a prediction model, which can help doctors predict the likelihood of anemia in elderly patients taking linezolid. This can guide clinicians in monitoring and managing patients more effectively, potentially reducing the occurrence of anemia and ensuring safer use of linezolid in elderly populations.

Development and Validation of a Risk Prediction Model of Linezolid-induced Thrombocytopenia in Elderly Patients

Establishment and validation of a risk prediction model incorporating concentrations of linezolid and its metabolite PNU142300 for linezolid-induced thrombocytopenia

Therapeutic Drug Monitoring of Linezolid and Exploring Optimal Regimens and a Toxicity-Related Nomogram in Elderly Patients: a Multicentre, Prospective, Non-Interventional Study.

High frequency of thrombocytopenia in patients with acute-on-chronic liver failure treated with linezolid

Risk factors for thrombocytopenia in patients receiving linezolid therapy: a systematic review and meta-analysis

Development and validation of a risk prediction model for linezolid-induced anemia in elderly patients: a retrospective cohort study

Prediction of risk factors for linezolid-induced thrombocytopenia based on neural network model

Effect of Platelet Parameters on Linezolid-Related Thrombocytopenia in Hospitalized Patients.

Meta-analysis of Risk Factors for Thrombocytopenia Related to Linezolid

Therapeutic Drug Monitoring and Receiver Operating Characteristic Curve Prediction May Reduce the Development of Linezolid-Associated Thrombocytopenia in Critically Ill Patients

Model Based Identification of Linezolid Exposure–toxicity Thresholds in Hospitalized Patients

Association of clinical factors with thrombocytopenia in patients receiving linezolid treatment: a retrospective study

Retrospective Study of Adverse Drug Reaction(ADR) Induced by Linezolid in Hematological System

Clinical efficacy of linezolid used by the elderly with renal dysfunction and its effect on platelets

Analysis of the Effect Factors of Thrombocytopenia Associated with Linezolid

A standard dose of linezolid put patients with hepatic impairment at risk of overexposure

A standard dose of linezolid puts patients with hepatic impairment at risk of overexposure

Towards a better detection of patients at-risk of linezolid toxicity in clinical practice: a prospective study in three Belgian hospital centers

Dose Optimization of Linezolid in Critically Ill Patients Based on A Population Pharmacokinetics Model: A Two-center Prospective Interventional Study

The clinical features and drug resistance of 10 patients with linezolid-nonsusceptible Enterococcal blood stream infection

Identifying and Targeting Prediction of the PI3K-AKT Signaling Pathway in Drug-Induced Thrombocytopenia in Infected Patients Receiving Linezolid Therapy: A Network Pharmacology-Based Analysis